Brief Summary

Skip to Participation Criteria

A DNA hypermethylation of the gene locus SHOX2 can be frequently found in lung cancer tissue. The purpose of this study is to determine whether the assessment of the hypermethylation level of SHOX2 in specimens obtained by endosonographic guided bronchoscopy makes a contribution to lung cancer staging.

• Study Type: Observational
• Study Design: Observational Model: Cohort, Time Perspective: Prospective
• Study Primary Completion Date: February 2012

Interventions Used in this Clinical Trial

• Other: No intervention

Arms, Groups and Cohorts in this Clinical Trial

• Lung cancer with lymph node involvement

Outcome Measures for this Clinical Trial

Primary Measures

• Diagnostic Performance of SHOX2
  • Time Frame: one Year
    Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

• clinical diagnosis of lung cancer
• enlarged mediastinal or hilar lymph nodes (>10 mm)

Exclusion Criteria

• clinical condition which excludes general anesthesia

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 90 Years

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

• Lead Sponsor
  • University Hospital, Essen
• Collaborator
  • Epigenomics, Inc
• Provider of Information About this Clinical Study
  • Principal Investigator: Kaid Darwiche, Dr. med. Kaid Darwiche - University Hospital, Essen
• Overall Contact(s)
  • Kaid Darwiche, MD, +49201433, kaid.darwiche@ruhrlandklinik.uk-essen.de